Registration of Four Dry Bean Germplasms Resistant to Common Bacterial Blight: ICB‐3, ICB‐6, ICB‐8, and ICB‐10

Vollständiger Abstract

Worum geht es in dieser Arbeit?

<h4>Purpose</h4>To describe a case of refractory unilateral PEVAC macular edema initially treated with intravitreal faricimab injections.<h4>Methods</h4>Medical and imaging records were evaluated. Tracked optical coherence tomography (OCT) B scans were reviewed to assess intra-retinal fluid and exudation.<h4>Results</h4>A 79-year-old man with unilateral chronic macular edema secondary to PEVAC lesion underwent three monthly intravitreal faricimab injections with completely resolution of the fluid and visual recovery. A presumed thrombotic mechanism of the exudative vascular complex might have occurred in this case.<h4>Conclusion</h4>After conducting a literature review on June, 2025, utilizing PubMed and Google Scholar, using the key words PEVAC, LRCA and faricimab therapy, there wasn't any prior reports of PEVAC case treated by a bi-specific antibody directed against Ang2 and VEGF (faricimab). Though, limitted by a short follow-up time (9 months), this unique clinical experience should be shared to inform that faricimab may lead to early remarkable anatomical and functional improvement in eyes with no responsive PEVAC lesions.

Abstract: PubMed · Datensatz